Right. Because everything on twitter is legit. It's not like people ever pay for tweets or release false rumors on twitter.

This company has been pulling the exact same shenanigans since 1998. It doesn't take 17 years to get a medical device like this approved. LLBO is an ATM machine for Jim Holmes. Nothing more.

The 13G was filed because IDRA sold most of their shares, such that they are no longer a 5% owner in the company. They now own less than 1% of the company.

http://insidercow.com/institution/subject.jsp;jsessionid=1468DF71D29B5A6274D66E0A5F5CFD44?subject=0000861838&company=IDRA

SCTPF

This stock looks to be a good longterm hold with excellent prospects. They are developing a cancer immunotherapy that targets CD47. This is one of the newest approaches to treating cancer. Stanford is currently leading the pack in doing the research. (SCTPF is about one year behind.) Once Stanford's early studies are completed in 2014, you'll likely see biotechs quickly getting on the CD47 bandwagon, and CD47 stocks should then take off.

The other very nice thing about this stock is that they just did a large round of financing through a private placement. The leader of the pack in this financing? Baker Brothers. So you know this stock is legit, despite being OTC.

The potential here for incredible longterm gains is pretty good and I think there's a good shot at a double in 2014. (If CD47 takes off, this stock will go well past doubling given its low market cap.) The stock can be fairly illiquid (and shares are difficult to purchase even if you are sitting on the ask) so it is probably a better longterm hold than it is a trading stock. But given the low market cap here, I think it's worth it.

Not gonna happen before results. Data means everything. No smart biotech company would invest right now without seeing results, particularly because the previous trial failed. If we were going to see a partner for Z-160 prior to data, we'd have seen it many months ago.

For what it's worth, I'm long ZLCS and intend on holding some shares through data. If it is positive--and I think it will be--the next few years will see a ridiculous increase in share price. But I also use common sense when I invest, and common sense says a partner will not come until AFTER results.

Now if you're talking about Z-944 or any other pre-clinical possibilities, maybe a partnership will come this month. But don't count on it for Z-160.

Won't happen if you are talking about Z-160. A partner won't come until after results. It wouldn't make any sense to partner this close to results without knowing what the data looks like.

TICK TOCK

Price explosion imminent.

TLON - Who got caught holding the bag at the close? Shares converted for 5.6 cents today. Oops.

TLON was always a huge risk and is not indicative of the rest of the biotech sector. Biotech is the best sector be in! Just don't play the OTC stocks. Stick to solid NASDAQ plays. Plenty of money to be made.

People on several forums were suggesting early in the day that shareholders get out. Not sure what else to tell you. You're getting a little over 5 cents in cash per share. Then you have to hope that SPPI can actually sell Marqibo in order to maybe break even with a limited upsdie. Given their failures with their own drugs, I wouldn't have faith in SPPI. Sorry if you lost money here. It sucks, but there are always good opportunities out there in biotech. Just don't get too attached to any stock and be willing to see the forest through the trees.

Here you go:

http://investor.spectrumpharm.com/eventdetail.cfm?EventID=132306

TLON is being acquired by SPPI. The deal is not at all favorable to TLON shareholders. Except for... you guessed it--Deerfield Management. Deerfield looks out for no one but themselves.

Hahahahahahahahahahahaha!!!!!!!!! Thanks for the laugh. Clearly the market agrees--that's why it has dropped 50% in the past year.

Why is it that for so many posters every time the stock goes down it is because of "market manipulation", but every time the stock goes up, it's for some positive reason?

Isn't it possible that...

a) the shaky market right now is causing a lot of profit taking/shorting?

and/or

b) the market doesn't believe Belviq sales will be very good?

Not every drop is due to "market manipulation." Based on the IMS data today, it doesn't look like Belviq is going to be the big seller some think it will be, which explains the high short count. The next few months will be quite revealing.

Yep, I think double digits aren't too far off now. However, I think a capital raise will occur shortly after that happens.

I respectfully disagree. The stock price would never have dropped to the low 40s in the first place if dilution was priced in and the market felt that Marqibo would achieve decent sales. I wouldn't assume the stock won't go any lower. It might not, but thinking it definitely won't is dangerous. One thing does seem pretty clear, and that's that the company needs to be sold or partnered. Short of that, I don't really see the stock price making any significant upward movement. It'll stagnate or drop.

$heff bought. That's why.

Down. Company has no cash. You're going to see some pretty significant dilution very, very soon, unless they can pull a rabbit of a hat and sell or partner, which seems pretty unlikely at this point.

That statement was across ALL biotechs; not just ARNA. Have you checked his predictions for every biotech he made a prediction about in the past year? If not, it's not very fair to say that "he's wrong more than he's right".

I'm well aware of his history here. But he was right the first time ARNA got shot down by the FDA a few years ago. So this isn't the only time he's been right on ARNA. And it remains to be seen if he's wrong on Belviq sales.

He's right plenty, and it isn't because of luck. He was correct on SRPT, VRTX, and KERX having positive trials. He was also correct on AVEO, CLSN, and DCTH having bad news. Those are off the top of my head, but there are plenty more.

Shouldn't you be asking yourself that question? You're the one who posted this, which assumes he got lucky with his opinion:

There is a common connection among people who claim that Adam F is more wrong than right. They are always people who are in stocks that suffer bad news that Adam F called correctly, which leads me to believe that it's an emotionally driven assertion. I haven't taken the time to see how right or wrong Adam has been in the past year, but I'd also wager that neither have the people claiming that he's wrong more than right. Unless they cherry pick, which doesn't count.

The fact still stands though. He was right on this one, and it's disingenious to suggest he randomly got lucky.

Failing to see the forest through the trees is never good when investing. It's fine to call someone out when they are wrong, but on the flip side give credit where credit is due.

I'll say it again: Belviq sales are going to be horrible.

Adam F called it correctly, more or less. People hate on the guy, but it's always wise to consider the naysayers' opinions. He's also going to be right on lackluster Belviq sales.

It's not the end of the world, but you can make a heck of a lot more money elsewhere between now and the closing of the merger. Just saying.

It might work out in the end, but it will take a long time. Phase 2 data for their lead drug isn't even due until 2014. In the meanwhile, the share price is likely to decline significantly, which is why I sold.

Sold my stock at the open of pre-market. The PIPE financing reeks, imo, and shareholders were given a bad deal. Massive dilution is on the way because of this PIPE, and the share price will drop significantly over the next few months into the closing of the merger. Hence the need for the R/S. Best of luck to all who intend on staying in for the long haul.

I've held shares here for awhile and have been mildly bullish, but spot is probably right. The stock is likely going to drop sharply tomorrow, unless something positive not included in the press release comes out in the conference call tomorrow. It was always a wildcard play though.

Dunno. Here's hoping it is meaningful and not just a CPRX-like pump and dump. (Because that stock will crash hard very soon.)

Yes. It's been featured on local TV and other small-time news multiple times for 15 years. It's not that hard to get something like that on a local news station. Let me know when it makes it onto CNN or 60 Minutes.

Read up on the history of this company. You can make a lot of money trading this, but if you honestly believe FWS is worth investing in for more than a quick flip, your wallet will be empty. Best of luck.

1. A reverse split will come if the DTC chill is removed.

2. FWS will likely never make it to market. If it was a reality, don't you think it would have made it by now? It doesn't take 15 years for a diagnostic test to make it to market.

3. If by some miracle, FWS did make it to market, it wouldn't sell. Have you seen how ridiculously cumbersome it is?

4. This stock is a scam. It is naive to believe otherwise. Trade it wisely.

Only if they already owned more than 5% or their new purchase pushed them over 5%.

Wrong, NASDAQ doesn't delist stocks early. They only de-list when the de-listing date occurs, if the company hasn't asked for an extension or met the requirements to avoid de-listing.

In summary, the company is no longer investing in clinical trials or developmental activities. What this tells me is a couple of important things.

1. They are burning very, very little cash. It is all going toward administrative expenses, salaries, and Stifel.

2. If they are not investing in developmental activities, they are not doing anything related to MATCH right now.

Only one logical conclusion: Given that MATCH is the only thing the company has, they are, in fact, aggressively looking to sell the company. It's a waiting game at this point, and a question of how much they'll get.

Definitely. Apple too!

It makes sense that management would choose bankruptcy over selling the company to a big fish before running out of cash. Bankruptcy is the most logical conclusion. It's just good business sense to get the smallest return on your shares as possible.

Ha. Not quite. Minnewaska State Park in upstate NY.

The only downside risk is really how long it takes. The longer it takes, the more the stock will drift down. I think it will come before the end of Q2 and hopefully in the early part.

ONCS Not sure if anybody has mentioned this one here, but it's worth taking a look at. Lots of potential with several catalysts this year. Chart also looks like it wants to move north after having bottomed out a couple of weeks ago.

Why would he buy shares that he knew were guaranteed to drop due to the discontinuation of their pipeline drugs? Only a fool would do that.

Uh, yeah it is. It's called insider trading. Here's a nice definition for you:


Definition of 'Insider Trading'
The buying or selling of a security by someone who has access to material, nonpublic information about the security.

Investopedia explains 'Insider Trading'
Insider trading can be illegal or legal depending on when the insider makes the trade: it is illegal when the material information is still nonpublic--trading while having special knowledge is unfair to other investors who don't have access to such knowledge. Illegal insider trading therefore includes tipping others when you have any sort of nonpublic information. Directors are not the only ones who have the potential to be convicted of insider trading. People such as brokers and even family members can be guilty.

Insider trading is legal once the material information has been made public, at which time the insider has no direct advantage over other investors. The SEC, however, still requires all insiders to report all their transactions. So, as insiders have an insight into the workings of their company, it may be wise for an investor to look at these reports to see how insiders are legally trading their stock.